ArticleInternational journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group2022
3D margin assessment predicts local tumor progression after ablation of colorectal cancer liver metastases.
Article in International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Estimation of tumor coverage after RF ablation of hepatocellular carcinoma using single 2D image slices.International journal of computer assisted radiology and surgery · 2025Trial
- Software-based versus visual assessment of the minimal ablative margin in patients with liver tumours undergoing percutaneous thermal ablation (COVER-ALL): a randomised phase 2 trial.The lancet. Gastroenterology & hepatology · 2025Trial
- Intra-procedural CT control versus ultrasound only in ultrasound-guided thermal ablation of colorectal liver metastases: a single-centre cohort study.Surgical endoscopy · 2026Article
- Review
- Article
- Robotic-assisted needle placement in CT-guided percutaneous ablation in the abdomen: the SaFE post-market study.La Radiologia medica · 2026Article
- Automated Deformable Registration and Three-dimensional Margin Assessment for Predicting Local Recurrence after Lung Thermal Ablation.Radiology. Imaging cancer · 2026Article
- The local efficacy and influencing factors of ultrasound-guided percutaneous radiofrequency ablation in sub-cardiac hepatic tumor: A 7-year experience at a single center.Abdominal radiology (New York) · 2026Article
- Association between Three-dimensional Margin Assessment and Local Tumor Control in Percutaneous Lung Cryoablation of Colorectal Metastases.Radiology. Imaging cancer · 2026Article
- The effects of measurement errors on minimum ablative margins after thermal ablation of liver tumors: a simulation study.CVIR oncology · 2026Article
- Article
- Predicting Tumor Recurrence with Early 18F-FDG PET-CT After Thermal and Non-Thermal Ablation.Current oncology (Toronto, Ont.) · 2025Article
- Interventional Oncology for Colorectal Liver Metastases: From Local Cure to Salvage Therapy.Biomedicines · 2025Review
- CT-guided Thermal Ablation of Liver Tumors Using Intraprocedural CT-CT Fusion for Applicator Position and Ablation Completeness Assessment: a Single-Center Comparative Analysis.Cardiovascular and interventional radiology · 2025Article
- Quantitative Ablation Confirmation Methods in Percutaneous Thermal Ablation of Malignant Liver Tumors: Technical Insights, Clinical Evidence, and Future Outlook.Radiology. Imaging cancer · 2025Review
- Prognostic Comparison of Complete vs. Incomplete Radiofrequency Ablation for Colorectal Liver Metastases: A Multicenter Prospective Study.Cancer medicine · 2025Article
- Evaluation of the Ki-67 labeling index on immediate pre-ablation biopsies as a predictive biomarker of local recurrence of colorectal cancer liver metastases.Cytotechnology · 2025Article
- Multicenter and inter-software evaluation of ablative margins after thermal ablation of colorectal liver metastases.European radiology · 2025Article
- Microwave Ablation of Refractory Oligometastatic Non-Small Cell Lung Cancer in the Liver.Journal of vascular and interventional radiology : JVIR · 2025Article
- Evaluation of Local Tumor Outcomes Following Microwave Ablation of Colorectal Liver Metastases Using CT Imaging: A Comparison of Visual versus Quantitative Methods.Radiology. Imaging cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo determine the feasibility and prognostic value of 3D measuring of the ablation margins using a dedicated image registration software.
methodsThis retrospective study included 104 colorectal liver metastases in 68 consecutive patients that underwent microwave ablation between 08/2012 and 08/2019. The minimal ablation margin (MM) was measured in 2D using anatomic landmarks on contrast enhanced CT(CECT) 4-8 weeks post-ablation, and in 3D using an image registration software and immediate post-ablation CECT. Local tumor progression (LTP) was assessed by imaging up to 24 months after ablation. A blinded interventional radiologist provided feedback on the possibility of additional ablation after examining the 3D-margin measurements.
resultsThe 3D-margin assessment was completed in 79/104 (76%) tumors without the need for target manipulation. In 25/104 (24%) tumors, manipulation was required due to image misregistration. LTP was observed in 40/104 (38.5%) tumors: 92.5% vs 7.5% for those with margin <5mm vs ≥5mm, respectively (
conclusionImage registration software can measure ablation margins and detect MM under 5 mm intraoperatively, with significantly higher sensitivity than the 2D technique using landmarks on the post-ablation CECT. The identification of a margin under 5 mm is strongly associated with LTP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.